CN Patent

CN111182900A — Sma的新疗法

Assigned to F Hoffmann La Roche AG · Expires 2020-05-19 · 6y expired

What this patent protects

本发明涉及用于治疗脊髓性肌萎缩症(SMA)的7‑(4,7‑二氮杂螺[2.5]辛‑7‑基)‑2‑(2,8‑二甲基咪唑并[1,2‑b]哒嗪‑6‑基)吡啶并[1,2‑a]嘧啶‑4‑酮，用于治疗SMA的其药物组合物，其治疗方法。

USPTO Abstract

本发明涉及用于治疗脊髓性肌萎缩症(SMA)的7‑(4,7‑二氮杂螺[2.5]辛‑7‑基)‑2‑(2,8‑二甲基咪唑并[1,2‑b]哒嗪‑6‑基)吡啶并[1,2‑a]嘧啶‑4‑酮，用于治疗SMA的其药物组合物，其治疗方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111182900A
Jurisdiction
CN
Classification
—
Expires
2020-05-19
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.